Global Chorionic Gonadotrophin Market Size By Type (500U, 1000U), By Application (Undescended Testicles In Adolescence, Male Infertility), By Region, And Segment Forecasts, 2023 to 2032

The Global Chorionic Gonadotrophin Market was valued at USD 725 million in 2023 and is projected to reach USD 1.21 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. The growth of the market is primarily driven by the increasing incidence of infertility, rising awareness of assisted reproductive technologies (ART), and expanding applications in veterinary and research sectors. Chorionic gonadotrophin, a key hormone used in fertility treatments and hormonal therapies, continues to gain relevance across both human and animal health industries.

Drivers:

1. Rising Prevalence of Infertility Globally

Lifestyle changes, stress, environmental toxins, and delayed parenthood are contributing to an increasing rate of infertility among both men and women. This has led to heightened demand for fertility treatment solutions such as human chorionic gonadotrophin (hCG).

2. Growing Use in Assisted Reproductive Technologies (ART)

hCG is a critical component in ART procedures like in-vitro fertilization (IVF). The rising success rates of ART and growing accessibility of fertility clinics worldwide are fueling market demand.

3. Expanding Veterinary Applications

In veterinary medicine, chorionic gonadotrophin is widely used to treat reproductive disorders in livestock. The rising global livestock population and efforts to improve animal productivity are driving adoption in this segment.

Restraints:

1. Adverse Side Effects and Contraindications

Despite its benefits, hCG use may be associated with complications such as ovarian hyperstimulation syndrome (OHSS) and contraindications in hormone-sensitive cancers, which may restrict its adoption.

2. Stringent Regulatory Framework

The market is subject to strict regulatory approvals due to the hormone’s biological nature and potential side effects, which can delay product launches and market entry for new players.

Opportunity:

1. Rising Demand in Emerging Economies

Countries in Asia-Pacific and Latin America are witnessing an uptick in infertility awareness, medical tourism, and healthcare infrastructure development, creating new opportunities for chorionic gonadotrophin products.

2. Innovation in Drug Delivery Systems

The development of novel formulations and delivery methods (e.g., subcutaneous administration, extended-release injectables) offers potential to improve patient compliance and outcomes.

Market by System Type Insights:

Based on product type, the urinary-derived hCG segment held the largest market share in 2023 due to its extensive use in fertility treatments and widespread availability. However, the recombinant hCG segment is projected to witness faster growth, fueled by improved purity, safety, and controlled manufacturing processes.

Market by End-use Insights:

In terms of end use, fertility clinics emerged as the dominant segment in 2023, accounting for over 40% of the market share. This is attributed to the increasing number of ART procedures globally. The research and academic institutes segment is also expected to expand significantly due to ongoing investigations into hormone therapies and reproductive biology.

Market by Regional Insights:

North America led the global chorionic gonadotrophin market in 2023, driven by advanced healthcare infrastructure, high ART adoption rates, and supportive insurance policies. Meanwhile, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, supported by a growing patient pool, rising healthcare investments, and expanding awareness of infertility treatment options.

Competitive Scenario:

Major companies operating in the global chorionic gonadotrophin market include Merck & Co., Inc., Ferring Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, IBSA Institut Biochimique SA, Lupin Pharmaceuticals, Inc., Bayer AG, and Pfizer Inc. These players focus on expanding production capacity, strategic partnerships, and regulatory approvals to enhance their global footprint.

Scope of Work – Global Chorionic Gonadotrophin Market

Key Market Developments:

July 2023: Merck launched a new recombinant hCG product with improved pharmacokinetics for ART use in the European market.

March 2024: Ferring Pharmaceuticals expanded its manufacturing facility in India to meet rising demand for fertility hormone treatments.

January 2025: Sun Pharmaceutical received US FDA approval for its biosimilar recombinant hCG, enabling entry into the competitive U.S. fertility drug market.

FAQs:

1) What is the current market size of the Global Chorionic Gonadotrophin Market?

The market size stood at USD 725 million in 2023.

2) What is the major growth driver of the Global Chorionic Gonadotrophin Market?

Rising infertility rates and growing ART adoption are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Chorionic Gonadotrophin Market?

North America dominated the market in 2023, but Asia-Pacific is expected to grow at the highest rate.

4) Which segment accounted for the largest market share in the Global Chorionic Gonadotrophin Market?

The urinary-derived hCG segment led the market in 2023.

5) Who are the key market players in the Global Chorionic Gonadotrophin Market?

Key players include Merck & Co., Inc., Ferring Pharmaceuticals, Sun Pharmaceutical, and Pfizer Inc.